Interleukin-17: from clone to clinic
24 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Improving on "Natural" Rodent Antibodies
-
26 min
1. The immunogenicity problem in antibody therapy- Prof. Herman Waldmann
-
32 min
2. Antibodies by protein engineering- Prof. Sir Gregory Winter
-
60 min
3. The generation of diversity in antibody genes- Prof. Michael Neuberger
-
51 min
4. Innate immunity to retroelements by human AID/APOBEC3 proteins- Prof. Reuben Harris
-
36 min
5. Fc receptors and antibody effector functions- Dr. Mike Clark
-
57 min
6. Antibody engineering of Fc effector functions- Dr. Mike Clark
-
35 min
7. Antibody engineering: beginnings to bispecifics and beyond- Dr. Ian Wilkinson
- Antibodies in Cancer Therapy
-
41 min
8. Monoclonal antibodies and the ErbB system in human cancer- Prof. Mark Greene
-
71 min
9. Checkpoint blockade in cancer immunotherapy- Prof. James Allison
-
45 min
10. Monoclonal antibodies in haemato-oncology- Prof. Mark Cragg
- Diagnostic Antibodies
-
46 min
11. Monitoring therapy with antibodies- Dr. Geoffrey Hale
- Cell Surface Glycoproteins on Cells of the Immune System
-
38 min
12. Cell surface glycoproteins on cells of the immune system- Prof. Neil Barclay
- Antibodies as Immunosuppressants
-
29 min
13. Monoclonal antibodies to induce therapeutic immunological tolerance- Prof. Herman Waldmann
-
29 min
14. Antibodies to control or prevent type 1 diabetes- Dr. Robert Hilbrands
-
48 min
15. Antibody therapy of multiple sclerosis- Dr. Alasdair Coles
- Prof. Alastair Compston
-
42 min
16. Monoclonal antibodies in the management of rheumatoid arthritis- Prof. John Isaacs
-
40 min
-
30 min
- Archived Lectures *These may not cover the latest advances in the field
-
26 min
19. Alemtuzumab (Campath-1H) in therapy of CLL- Prof. Kanti Rai
-
71 min
20. VEGF inhibitors for anti-angiogenic therapy- Prof. Kari Alitalo
- Dr. Bronislaw Pytowski
-
26 min
21. Human antibodies produced in mice- Dr. Marianne Bruggemann
-
52 min
22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man- Prof. Christian Larsen
-
55 min
23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity- Prof. Thomas Tedder
-
45 min
24. Anti-IL-2 receptor antibodies as models for cancer therapy- Prof. Thomas Waldmann
-
58 min
25. Anti TNF therapy in rheumatoid arthritis- Prof. Marc Feldmann
-
36 min
26. Novel immunotherapeutic proteins: immunoligand- Prof. Terry Strom
-
21 min
27. Diagnostic immunohistopathology- Prof. David Mason
-
56 min
28. Antibodies in the control of type I diabetes- Prof. Lucienne Chatenoud
-
43 min
29. The challenge of targeting toxins to tumors- Prof. Ben Seon
-
38 min
30. Antibody depletion therapy in transplantation: implications for tolerance- Prof. Laurence Turka
-
36 min
31. Antibodies as anti-virals- Prof. Dennis Burton
Printable Handouts
Navigable Slide Index
- Introduction
- Costimulation blockade: bench-to-bedside & back
- Fifty years of transplantation
- US transplants by year
- US organ transplants (N=21,516)
- Improved short term outcomes
- Immunosuppression for renal transplantation
- Activated T cells play central role in rejection
- Current immunosuppressive agents target T cells
- Drug target distribution and toxicity
- Unaffected long term outcomes
- Costimulation blockade: inadequate results
- Costimulation: a component of T cell activation
- Critical costimulatory pathways
- CD28 signaling
- Drug toxicity - traditional vs. cosimulation blocking
- CTLA-4- second receptor for B7 activation antigen
- CD28 blockade: lessons from early murine studies
- Transplantation tolerance induced by CTLA4-Ig
- Rhesus renal allograft model
- Effect of CTLA4-Ig on renal allograft survival
- Studies results
- CTLA4Ig treatment of psoriasis is beneficial
- CTLA4Ig effective for treatment of RA
- CD28 blockade: efficacy in humans vs. mice
- Structural basis for co-stimulation by CTLA-4/B7-2
- Creation of belatacept (LEA29Y)
- LEA29Y: more potent co-stimulation blockade
- LEA29Y renal allograft protocol
- LEA29Y treatment is beneficial for renal allograft
- Path to CNI free trials in renal transplantation
- IM103-100 study: rationale and design
- The belatacept study group
- LEA29Y phase II dose-finding study design
- Study endpoints
- Primary endpoint: acute rejection
- Time to onset of acute rejection
- Summary key secondary endpoints - 12 months
- Key safety events
- IM103-100 summary
- Belatacept/LEA29Y: next steps
- Costimulation blockade: CD40
- Costimulatory pathways - CD40 & CD154
- TNF/TNFR superfamily members
- X-linked hyper-IgM syndrome
- CD154: master regulator of T cell responses
- Anti-CD154 mAbs in transplantation
- Anti-CD154 in humans
- Platelet - derived CD154
- CD40L stabilizes arterial thrombi
- Targeting CD40: properties of Chi220
- Islet transplantation in non-human primates
- LEA29Y/Chi220 islet protocol
- Prolonged islet allograft survival w/ Chi220/LEA29Y
- Targeting CD154-CD40 in transplantation
- Costimulation blockade: summary
- Summary
Topics Covered
- Clinical transplantation
- Current immunosuppression
- T-cell activation
- Co-stimulatory pathways
- CD28 pathway
- Mechanisms of action and clinical development
- CD40-CD154 pathway
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Larsen, C. (2007, October 1). New strategies to prevent transplant rejection: from molecules to mice to monkeys to man [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/OWTW7371.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Christian Larsen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
New strategies to prevent transplant rejection: from molecules to mice to monkeys to man
A selection of talks on Immunology & Inflammation
Hide